BYSI · BeyondSpring Inc.
AI read · Neutral
The AI's read
The FDA designation can bring more chances to discuss the treatment with regulators, but it is not an approval. Biolin is funding work at Chinese trial sites for about half the planned patients, and BeyondSpring keeps access to those results. In return, BeyondSpring sold the subsidiary that held its majority stake in Bulin. The company also says it is still seeking financing, and quarterly general and administrative costs rose from $0.7 million to $1.0 million. The report does not show that the trial support and regulatory progress outweigh the ownership and funding concerns.